FLUENT Reports Second Quarter 2026 Results

(MENAFN- GlobeNewsWire - Nasdaq) Q2 2026 Revenue brought in $17.1M
Ended quarter with $4.5 million of cash and cash equivalents
New Interim CEO appointed

TAMPA, Fla., Aug. 21, 2026 (GLOBE NEWSWIRE) -- FLUENT Corp. (CSE: FNT.U) (OTCQB: CNTMF) ("FLUENT" or the "Company"), a vertically-integrated, multi-state cannabis company, today announced its financial and operating results for the second quarter ended June 30, 2026. Unless otherwise indicated, all financial results are presented in U.S. dollars.

Management Commentary
“As we move through the second half of the year, our priorities remain clear,” said Matt Mundy, Interim CEO and Chief Legal Officer of the Company.“We are focused on completing the Vireo transaction while continuing to optimize our operational footprint, particularly in Florida, where we are seeing promising results from the actions taken to date. At the same time, we remain disciplined in managing the business, with a continued focus on reducing operating costs, improving efficiency, and strengthening the Company's financial position.”

Q2 2026 Financial Highlights (vs. Q2 2025)

• Revenue from continuing operations was $17.1 million compared to $22.8 million.
• Florida revenue was $12.8 million compared to $19.2 million.
• Gross profit before fair value adjustments¹ from continuing operations was $4.3 million or 25.2% of revenue, compared to $8.9 million or 38.8% of revenue.
• Adjusted EBITDA² was $0.3 million compared to $3.6 million. The decrease was primarily due to continued downward pressure on retail prices in Florida, resulting in a corresponding reduction in the fair value of biological assets.
• Cash flow provided by operations was $0.8 million compared to $3.2 million.
• On June 30, 2026, the Company had approximately $4.5 million of cash and cash equivalents and $79.7 million of total debt outstanding, with approximately 692 million shares outstanding on an as-converted basis, compared to $22.9 million of cash and cash equivalents and $78.1 million of total debt, with approximately 687 million shares outstanding on an as-converted basis on June 30, 2025.

____________________________

¹ Gross profit before fair value adjustments is a non-IFRS financial measure that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies. The Company calculates gross profit before fair value adjustments from gross profit plus (minus) the changes in fair value of biological assets, as presented in the consolidated statement of operations.
² Adjusted EBITDA is a non-IFRS financial measure that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies. The Company calculates Adjusted EBITDA as EBITDA (being calculated as the net income (loss), plus (minus) interest expense (income) and finance transactions costs, plus taxes, plus depreciation and amortization) plus (minus) the changes in fair value of biological assets, plus (minus) the changes in fair market value of derivatives, plus (minus) certain one-time non-operating expenses, as determined by management.

The Company's condensed interim consolidated financial statements as of June 30, 2026 and for the three and six months ended June 30, 2026 (the“Interim Financial Statements”) have been prepared assuming that the Company will continue as a going concern. As disclosed in the Interim Financial Statements, as of June 30, 2026, certain conditions indicate the existence of events and circumstances that may cast significant doubt on the Company's ability to continue as a going concern.

The Company continues to pursue strategic initiatives intended to strengthen its liquidity position and support ongoing operations. These initiatives include (i) entering into the arrangement agreement with Vireo Growth Inc. (“Vireo”) as previously disclosed by the Company on April 30, 2026, whereby, among other things, Vireo has agreed to acquire all of the issued and outstanding common shares of the Company (after conversion of all (a) proportionate voting shares of the Company and (b) non-voting, non-participating exchangeable shares of the Company) for subordinate voting shares of Vireo (the“Vireo Shares”) on the basis of 0.0705359 of a Vireo Share for each Company common share held (the“Vireo Arrangement”) and (ii) entering into a definitive agreement with Legacy Therapeutics, LLC (“Legacy”) as previously disclosed by the Company on May 1, 2026, whereby, among other things, Legacy has agreed to acquire the Company's Texas operations for an aggregate purchase price equal to $30 million. While management believes these initiatives may provide a pathway to additional capital and improved liquidity, the completion of these transactions are subject to, among other things, satisfaction of all conditions to closing (closing of the Vireo Arrangement has been approved by shareholders and the court, but remains subject to the receipt of other regulatory and third-party approvals) and their success is subject to various conditions not wholly within the Company's control. The Company's focus on cost reductions continued throughout Q2 2026, demonstrated by the closure of the Ruskin cultivation facility in Florida and continued efforts to optimize the Company's operations and retail footprint, while identifying opportunities for further operational efficiencies and improvements across the business.

Recent Operational Highlights

Company Footprint:

• As of the end of the reporting period, FLUENT operates a total of 34 retail locations and 7 production facilities across its key markets of Florida, New York, and Texas.

Florida:

• Operated 32 retail locations and four production facilities.
• An additional retail facility opened in July 2026 in Palm Bay, Florida.

New York:

• Operated one retail location and two production facilities in Q2 2026.
• Buffalo cultivation facility reached full operating capacity and contributed 1.7 million grams of production.

Texas:
·Entered definitive agreement to sell Texas operations on May 1, 2026, pending regulatory approval and satisfaction of customary closing conditions.

Conference Call

The Company will not host an earnings call for the quarter.

About FLUENT Corp.

FLUENT, a national cannabis consumer packaged goods company and retailer, is dedicated to being one of the highest quality cannabis companies for the communities it serves. This is driven by FLUENT's unrelenting commitment to operational excellence in cultivation, production, distribution, and retail experience. FLUENT produces an assortment of cannabis products under a diverse portfolio of brands including MOODS, Knack, Wandr, Bag-O and Hyer Kind. FLUENT operates in Florida, New York, and Texas.

Headquartered in Tampa, Florida, FLUENT employs approximately 550 employees across 6 cultivation and manufacturing facilities and 34 active retail locations.

FLUENT's common shares trade on the Canadian Securities Exchange under the symbol“FNT.U” and on the OTCQB Venture Market under the symbol“CNTMF”. For more information about the Company, please visit and investors.getFLUENT.com/.

Forward-Looking Information
Certain information in this news release may constitute forward-looking information within the meaning of applicable securities laws and may also contain statements that may constitute "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved" or similar expressions and includes, but is not limited to, statements with respect to the Company's commitment to and expectations regarding optimizing the Company's operational and retail footprint; reducing operating costs, improving efficiency, and strengthening the Company's financial position; the Company's ability to continue as a going concern; the satisfaction or waiver of the closing conditions in the definitive agreements entered into by the Company with each of Vireo and Legacy; the Company's continued pursuit of strategic initiatives and their intended outcome on the Company's liquidity position, capital and ongoing operations; and the identification of opportunities for further operational efficiencies and improvement across the business. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent the Company's expectations, estimates, and projections regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company's control.

Forward-looking information is necessarily based on many opinions, assumptions, and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions, and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in the public documents of the Company available on its SEDAR+ profile at These factors are not intended to represent a complete list of the factors that could affect the Company; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

The Company, through several of its subsidiaries, is directly involved in the manufacture, possession, use, sale, and distribution of cannabis in the adult-use and medical cannabis marketplace in the United States. Local state laws where the Company operates permit such activities however, investors should note that there are significant legal restrictions and regulations that govern the cannabis industry in the United States under federal law in the United States. Cannabis remains a scheduled drug under the United States Controlled Substances Act and, subject to certain exceptions in relation to medical cannabis, illegal under federal law in the United States to, among other things, cultivate, distribute, or possess cannabis in the United States. Financial transactions involving proceeds generated by, or intended to promote, cannabis-related business activities in the United States may form the basis for prosecution under applicable United States federal money laundering legislation.

While the approach to enforcement of such laws by the federal government in the United States has trended toward nonenforcement against individuals and businesses that comply with adult-use and medical cannabis programs in states where such programs are legal, strict compliance with state laws with respect to cannabis will neither absolve the Company of liability under United States federal law, nor will it provide a defense to any federal proceeding which may be brought against the Company. The enforcement of federal laws in the United States is a significant risk to the business of the Company and any proceedings brought against the Company thereunder may adversely affect operations and financial performance.

The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

For further information visit: and

Investor Relations Contact:
...

Media Contact:
...

Officer Contact:
Matt Mundy, Chief Legal Officer
(850) 972-8077

FLUENT CORP.
CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
(USD '000)
		June 30,		December 31,
		2026		2025
	Assets
	Current assets
	Cash and cash equivalents (includes restricted cash of $2,000 at June 30, 2026 and $4,500 at December 31, 2025)	$	4,515			$	8,910
	Accounts receivable, net		1,200				839
	Biological assets		2,042				2,670
	Inventories, net		14,131				12,815
	Prepaid expenses and other current assets		1,982				3,482
	Assets held for sale		1,857				-
	Total current assets	$	25,727			$	28,716
	Property and equipment, net		33,042				39,755
	Right-of-use assets, net		39,178				43,747
	Intangible assets, net		32,748				33,114
	Goodwill		1,525				1,525
	Other assets		1,423				1,725
	Total assets	$	133,643			$	148,582
	Liabilities and shareholders' deficit
	Current liabilities
	Accounts payable	$	10,956			$	6,942
	Accrued expenses		8,485				9,903
	Derivative liabilities		535				1,632
	Current portion of notes payable		9,620				1,253
	Lease obligations - current portion		5,506				5,474
	Liabilities directly associated with assets held for sale		691				-
	Total current liabilities	$	35,793			$	25,204
	Long-term liabilities
	Notes payable, net of current portion and financing costs		59,414				59,613
	Lease liabilities, net of current portion		61,353				65,982
	Deferred tax liabilities, net		4,028				4,053
	Uncertain tax position		64,653				60,146
	Provision liability, net of current portion		7,127				7,004
	Convertible notes, net		8,127				7,540
	Total long-term liabilities	$	204,702			$	204,338
	Total liabilities	$	240,495			$	229,542
	Shareholders' deficit
	Share capital		206,629				206,629
	Share-based compensation reserve		7,754				7,583
	Equity conversion feature		7,097				7,097
	Warrants		29,634				29,634
	Accumulated deficit		(356,770	)			(330,707	)
	Accumulated other comprehensive loss		(1,196	)			(1,196	)
	Total shareholders' deficit	$	(106,852	)		$	(80,960	)
	Total liabilities and shareholders' deficit	$	133,643			$	148,582

FLUENT CORP.
CONSOLIDATED STATEMENTS OF INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS)
(USD '000)
		For the three months ended		For the six months ended
		June 30, 2026		June 30, 2025		June 30, 2026		June 30, 2025
	Revenue, net of discounts	$	17,115			$	22,811			$	35,003			$	45,716
	Cost of goods sold		12,794				13,958				25,177				25,764
	Gross profit before fair value adjustments		4,321				8,853				9,826				19,952
	Fair value adjustments on inventory sold		2,567				(2,186	)			2,227				(2,487	)
	Unrealized gain (loss) on changes in fair value of biological assets		1,304				(999	)			(2,209	)			2,026
	Gross profit		8,192				5,668				9,844				19,491
	Expenses
	General and administrative		4,754				4,111				8,371				8,999
	Sales and marketing		3,959				5,886				8,492				11,647
	Depreciation and amortization		1,457				1,983				3,091				3,836
	Share-based compensation		81				293				171				318
	Total expenses		10,251				12,273				20,125				24,800
	Income (loss) from operations		(2,059	)			(6,605	)			(10,281	)			(5,309	)
	Other expense (income)
	Finance costs, net		6,649				5,566				11,790				9,907
	Change in fair value of derivative liability		(112	)			(219	)			(1,097	)			(676	)
	Change in remeasurement of provision liability		-				(4,790	)			-				(4,790	)
	Loss on disposal of assets, net		501				176				630				176
	Impairment of intangible assets, property and equipment, and right-of-use assets		664				-				664				-
	Gain on disposition of finance lease		(155	)			-				(393	)			-
	Other expense (income)		(236	)			(42	)			(433	)			(30	)
	Total other expense, net		7,311				691				11,161				4,587
	Income (loss) before income taxes		(9,370	)			(7,296	)			(21,442	)			(9,896	)
	Income tax expense		1,770				2,753				4,621				9,208
	Net income (loss) from continuing operations		(11,140	)			(10,049	)			(26,063	)			(19,104	)
	Net income (loss) from discontinued operations		-				377				-				682
	Net income (loss)	$	(11,140	)		$	(9,672	)		$	(26,063	)		$	(18,422	)
	Comprehensive income (loss)	$	(11,140	)		$	(9,672	)		$	(26,063	)		$	(18,422	)
	Net income (loss) per share
	Basic and diluted - continuing operations	$	(0.02	)		$	(0.02	)		$	(0.04	)		$	(0.04	)
	Basic - discontinued operations	$	-			$	0.00			$	-			$	0.00
	Diluted - discontinued operations	$	-			$	0.00			$	-			$	0.00
	Weighted average number of shares
	Basic number of shares		637,798,019				474,946,760				637,780,519				473,626,849
	Diluted number of shares		675,695,895				664,573,481				675,037,999				663,270,977

FLUENT CORP.
CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
(USD '000)
		For the six months ended June 30,
		2026		2025
	Cash flows used in operating activities
	Net loss	$	(26,063	)		$	(18,422	)
	Adjustments for non-cash items:
	Impairment of intangible assets, property and equipment, and right-of-use assets		664				-
	Unrealized (gain) loss on changes in fair value of biological assets		2,209				(2,026	)
	Realized (gain) loss on fair value amounts included in inventory sold		(2,227	)			2,487
	Share-based compensation expense		171				318
	Depreciation and amortization		8,956				12,108
	Accretion and interest expense		11,282				10,002
	Loss on disposition of fixed assets		1,151				176
	Gain on remeasurement of provision liability		-				(4,790	)
	Loss (gain) on lease modification		(427	)			2
	Net change in fair value of derivative		(1,097	)			(676	)
	Deferred tax expense (recovery)		(25	)			(1,192	)
	Net change in non-cash working capital
	Accounts receivable		(361	)			(175	)
	Biological assets		(10,057	)			(11,292	)
	Inventory		9,066				8,741
	Prepaid expenses and other current assets		2,441				1,173
	Right of use assets/liabilities		(3,622	)			(8,070	)
	Other assets		223				4,378
	Accounts payable		4,050				1,351
	Accrued expenses		(2,017	)			(806	)
	Uncertain tax position		4,507				9,478
	Income tax payable		-				(1,003	)
	Net cash provided by (used in) operating activities (see Note 3)	$	(1,176	)		$	1,762
	Cash flows used in investing activities
	Purchases of property and equipment		(1,211	)			(11,041	)
	Purchase of intangible assets		(316	)			-
	Net cash used in investing activities (see Note 3)	$	(1,527	)		$	(11,041	)
	Cash flows provided by (used in) financing activities
	Payment of lease obligations		(2,567	)			(2,142	)
	Proceeds from term loan amendment, net of financing costs		5,740				-
	Principal and interest repayments of notes payable		(4,865	)			(5,830	)
	Net cash provided by (used in) financing activities (see Note 3)	$	(1,692	)		$	(7,972	)
	Net change in cash		(4,395	)			(17,251	)
	Cash, beginning of period		8,910				40,106
	Cash, end of period	$	4,515			$	22,855

FLUENT CORP.
EBITDA AND ADJUSTED EBITDA CALCULATION
(USD '000)
		Three months ended
		June 30, 2026		June 30, 2025		Variance
	EBITDA - continuing and discontinued ops	$	1,585			$	4,910			$	(3,325	)
	Change in fair value of biological assets		(3,871	)			3,185				(7,056	)
	Change in fair market value of derivative		(112	)			(219	)			107
	Change in remeasurement of provision liability		-				(4,790	)			4,790
	Loss on disposal of assets, net		501				176				325
	Impairment expense		664				-				664
	Gain on disposition of finance lease		(155	)			-				(155	)
	Professional fees		1,563				10				1,553
	One-time employee costs		289				44				245
	Share-based compensation		81				293				(212	)
	Other non-recurring expense, net		(236	)			(42	)			(194	)
	Adjusted EBITDA - continuing and discontinued ops	$	309			$	3,567			$	(3,258	)
		Six months ended
		June 30, 2026		June 30, 2025		Variance
	EBITDA - continuing and discontinued ops	$	(700	)		$	11,511			$	(12,211	)
	Change in fair value of biological assets		(18	)			461				(479	)
	Change in fair market value of derivative		(1,097	)			(676	)			(421	)
	Change in remeasurement of provision liability		-				(4,790	)			4,790
	Impairment expense		664				-				664
	Gain on lease modifications		(393	)			-				(393	)
	Professional fees		2,219				91				2,127
	One-time employee costs		536				178				358
	Share-based compensation		171				318				(147	)
	Loss on disposal of assets		630				176				454
	Other non-recurring expense		(433	)			(30	)			(403	)
	Adjusted EBITDA - continuing and discontinued ops	$	1,578			$	7,239			$	(5,661	)

MENAFN21082026004107003653ID1111574122